Management of hepatitis B: Summary of a clinical research workshop Potential conflict of interest: Dr. Lok is a consultant and received grants from GlaxoSmithKline, Bristol-Myers Squibb, Idenix, Gilead, Roche, and Innogenetics.

Show simple item record

dc.contributor.author Hoofnagle, Jay H. en_US
dc.contributor.author Doo, Edward en_US
dc.contributor.author Liang, T. Jake en_US
dc.contributor.author Fleischer, Russell en_US
dc.contributor.author Lok, Anna S. -F. en_US
dc.date.accessioned 2007-09-20T18:27:30Z
dc.date.available 2008-09-08T14:25:13Z en_US
dc.date.issued 2007-04 en_US
dc.identifier.citation Hoofnagle, Jay H.; Doo, Edward; Liang, T. Jake; Fleischer, Russell; Lok, Anna S.F. (2007)."Management of hepatitis B: Summary of a clinical research workshop Potential conflict of interest: Dr. Lok is a consultant and received grants from GlaxoSmithKline, Bristol-Myers Squibb, Idenix, Gilead, Roche, and Innogenetics. ." Hepatology 45(4): 1056-1075. <http://hdl.handle.net/2027.42/56003> en_US
dc.identifier.issn 0270-9139 en_US
dc.identifier.issn 1527-3350 en_US
dc.identifier.uri http://hdl.handle.net/2027.42/56003
dc.identifier.uri http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=17393513&dopt=citation en_US
dc.description.abstract Chronic hepatitis B is caused by persistent infection with the hepatitis B virus (HBV), a unique DNA virus that replicates through an RNA intermediate produced from a stable covalently closed circular DNA molecule. Viral persistence appears to be due to inadequate innate and adaptive immune responses. Chronic infection has a variable course after several decades resulting in cirrhosis in up to one-third of patients and liver cancer in a proportion of those with cirrhosis. Sensitive assays for HBV DNA levels in serum have been developed that provide important insights into pathogenesis and natural history. Therapy of hepatitis B is evolving. Peginterferon induces long-term remissions in disease in one-third of patients with typical hepatitis B e antigen (HBeAg) positive chronic hepatitis B, but a lesser proportion of those without HBeAg. Several oral nucleoside analogues with activity against HBV have been shown to be effective in suppressing viral levels and improving biochemical and histological features of disease in a high proportion of patients with and without HBeAg, at least in the short term. What is uncertain is which agent or combination of agents is most effective, how long therapy should last, and which criteria should be used to start, continue, switch or stop therapy. Long-term therapy with nucleoside analogues may be the most appropriate approach to treatment, but the expense and lack of data on long-term safety and efficacy make recommendations difficult. Clearly, many basic and clinical research challenges remain in defining optimal means of management of chronic hepatitis B. (H EPATOLOGY 2007;45:1056–1075.) en_US
dc.format.extent 827560 bytes
dc.format.extent 3118 bytes
dc.format.mimetype application/pdf
dc.format.mimetype text/plain
dc.publisher Wiley Subscription Services, Inc., A Wiley Company en_US
dc.subject.other Life and Medical Sciences en_US
dc.subject.other Hepatology en_US
dc.title Management of hepatitis B: Summary of a clinical research workshop Potential conflict of interest: Dr. Lok is a consultant and received grants from GlaxoSmithKline, Bristol-Myers Squibb, Idenix, Gilead, Roche, and Innogenetics. en_US
dc.rights.robots IndexNoFollow en_US
dc.subject.hlbsecondlevel Internal Medicine and Specialties en_US
dc.subject.hlbtoplevel Health Sciences en_US
dc.description.peerreviewed Peer Reviewed en_US
dc.contributor.affiliationum Division of Gastroenterology, University of Michigan Medical Center, Ann Arbor, MI en_US
dc.contributor.affiliationother Liver Disease Research Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD ; fax: 301-480-7926 ; Bldg 31, Room 9A27, 31 Center Drive, NIH, Bethesda, MD 20892 en_US
dc.contributor.affiliationother Liver Disease Research Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD en_US
dc.contributor.affiliationother Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD en_US
dc.contributor.affiliationother Division of Antiviral Products, Food and Drug Administration, Silver Spring, MD en_US
dc.identifier.pmid 17393513 en_US
dc.description.bitstreamurl http://deepblue.lib.umich.edu/bitstream/2027.42/56003/1/21627_ftp.pdf en_US
dc.identifier.doi http://dx.doi.org/10.1002/hep.21627 en_US
dc.identifier.source Hepatology en_US
dc.owningcollname Interdisciplinary and Peer-Reviewed
 Show simple item record

This item appears in the following Collection(s)


Search Deep Blue

Advanced Search

Browse by

My Account

Information

Coming Soon


MLibrary logo